Jiangxi Kelun Medicine Industry Co. Ltd.

Main purpose: This study aims to study the pharmacokinetic characteristics of a single fasting intravenous drip of sodium butylphthalide injection (100 ml: 25 mg butylphthalide and 0.9 g sodium chloride) developed and produced by Jiangxi Kelun Pharmaceutical Co., Ltd. in healthy subjects; using sodium butylphthalide injection (ENBIP®, 100 ml: 25 mg butylphthalide and 0.9 g sodium chloride) produced by CSPC Pharmaceutical Group Enbi Pharmaceutical Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters of the two preparations and evaluate the human bioequivalence of the two preparations. Secondary purpose: To evaluate the safety of the test preparation and the reference preparation in healthy subjects.

The main purpose of the study is to evaluate the pharmacokinetic characteristics of the test preparation of pilocarpine hydrochloride eye drops and the reference preparation of pilocarpine hydrochloride eye drops (Vuity). The secondary purpose of the study is to investigate the safety of the test preparation and the reference preparation after administration to the subjects.

Primary objective: This study aims to study the pharmacokinetic characteristics of aguratimod tablets (25 mg) produced by Jiangxi Kelun Pharmaceutical Co., Ltd. after single fasting and postprandial oral administration; using aguratimod tablets (Edixin®, 25 mg) produced by Hainan Xiansheng Pharmaceutical Co., Ltd. as the reference preparation, compare the pharmacokinetic parameters Cmax, AUC0-t, AUC0-∞ of the two preparations, and evaluate the bioequivalence of the two preparations in humans. Secondary objective: Observe the safety of the test preparation and the reference preparation in healthy subjects.